Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Anti-CD19/CD22 CAR NK Cells in Relapsed/Refractory B-Cell Lymphoma
NCT03824964Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Feb 2019
- Primary completion
- Jan 2020
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/CD22 CAR NK cells in B cell lymphoma, sponsored by Allife Medical Science and Technology. Primary endpoint: Occurrence of treatment related adverse events as assessed by CTCAE v4.0 at 1 year. Status: unknown.
02
Drugs
anti-CD19/CD22 CAR NK cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03824964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824964.